Entity Details
Primary name |
PDE6A_HUMAN |
Entity type |
UniProt |
Source |
Source Link |
Details
Accession | P16499 |
EntryName | PDE6A_HUMAN |
FullName | Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha |
TaxID | 9606 |
Evidence | evidence at transcript level |
Length | 860 |
SequenceStatus | complete |
DateCreated | 1990-08-01 |
DateModified | 2021-06-02 |
Subcellular Location
Show/Hide Table
Subcellular Location |
Cell membrane |
Domains
Show/Hide Table
Domain | Name | Category | Type |
IPR002073 | 3'5'-cyclic nucleotide phosphodiesterase, catalytic domain | Domain | Domain |
IPR003018 | GAF domain | Domain | Domain |
IPR003607 | HD/PDEase domain | Domain | Domain |
IPR023088 | 3'5'-cyclic nucleotide phosphodiesterase | Family | Family |
IPR023174 | 3'5'-cyclic nucleotide phosphodiesterase, conserved site | Site | Conserved site |
IPR029016 | GAF-like domain superfamily | Family | Homologous superfamily |
IPR032958 | Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha | Family | Family |
IPR036971 | 3'5'-cyclic nucleotide phosphodiesterase, catalytic domain superfamily | Family | Homologous superfamily |
Diseases
Show/Hide Table
Disease ID | Source | Name | Description |
613810 | OMIM | Retinitis pigmentosa 43 (RP43) | A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. The disease is caused by variants affecting the gene represented in this entry. |
Drugs
Show/Hide Table
Drug | Name | Source | Type |
DB00201 | Caffeine | Drugbank | small molecule |
DB09283 | Trapidil | Drugbank | small molecule |
Interactions
0 interactions
Interactor | Partner | Sources | Publications | Link |